SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Vishwadeep Ahluwalia, Douglas M. Heuman, George Feldman, James B. Wade, Leroy R. Thacker, Edith Gavis, HoChong Gilles, Ariel Unser, Melanie B. White, Jasmohan S. Bajaj, Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis, Journal of Hepatology, 2015, 62, 1, 75

    CrossRef

  2. 2
    Won Hyeok Choe, June Sung Lee, Efficacy of Vaptans for Management of Ascites in Patients with Liver Cirrhosis, Korean Journal of Medicine, 2012, 82, 1, 22

    CrossRef

  3. 3
    Brianna E. Vaa, Sumeet K. Asrani, Winston Dunn, Patrick S. Kamath, Vijay H. Shah, Influence of Serum Sodium on MELD-Based Survival Prediction in Alcoholic Hepatitis, Mayo Clinic Proceedings, 2011, 86, 1, 37

    CrossRef

  4. 4
    Amy N. Sussman, Thomas D. Boyer, Management of Refractory Ascites and Hepatorenal Syndrome, Current Gastroenterology Reports, 2011, 13, 1, 17

    CrossRef

  5. 5
    Won Hyeok Choe, The use of vaptan in hyponatremic patients with liver cirrhosis, The Korean Journal of Hepatology, 2011, 17, 4, 335

    CrossRef

  6. 6
    M. Tejedor Bravo, A. Albillos Martínez, Avances en el tratamiento de la cirrosis hepática, Medicine - Programa de Formación Médica Continuada Acreditado, 2010, 10, 69, 4708

    CrossRef

  7. 7
    Lu Yin, Yourou Zheng, Xian Jia, Xingshu Li, Albert S.C. Chan, Efficient and promising asymmetric preparation of enantiopure tolvaptan via transfer hydrogenation with robust catalysts, Tetrahedron: Asymmetry, 2010, 21, 19, 2390

    CrossRef

  8. 8
    Mónica Guevara, Pere Ginès, Hiponatremia en la cirrosis hepática: patogenia y tratamiento, Endocrinología y Nutrición, 2010, 57, 15

    CrossRef

  9. 9
    Marilyn N Bulloch, Nathan A Pinner, Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia, Expert Review of Clinical Pharmacology, 2010, 3, 5, 601

    CrossRef